{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:28:26Z","timestamp":1790011706967,"version":"4.0.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,10,19]],"date-time":"2013-10-19T00:00:00Z","timestamp":1382140800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/2.5"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1007\/s40268-013-0029-1","type":"journal-article","created":{"date-parts":[[2013,10,18]],"date-time":"2013-10-18T08:33:22Z","timestamp":1382085202000},"page":"243-252","source":"Crossref","is-referenced-by-count":13,"title":["The Safety of Besifloxacin Ophthalmic Suspension 0.6\u00a0% Used Three Times Daily for 7\u00a0Days in the Treatment of Bacterial Conjunctivitis"],"prefix":"10.1007","volume":"13","author":[{"given":"Ranjan","family":"Malhotra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey","family":"Ackerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne S.","family":"Gearinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy W.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Allaire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,10,19]]},"reference":[{"key":"29_CR1","unstructured":"Besivance [package insert]. Rochester: Bausch & Lomb Inc (2009)."},{"key":"29_CR2","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1167\/iovs.06-1413","volume":"48","author":"E Protzko","year":"2007","unstructured":"Protzko E, Bowman L, Abelson M, for the AzaSite Clinical Study Group, et al. Phase 3 safety comparisons for 1.0% azithromycin in polymeric mucoadhesive eye drops versus 0.3% tobramycin eye drops for bacterial conjunctivitis. Invest Ophthalmol Vis Sci. 2007;48:3425\u20139.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"29_CR3","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1089\/jop.2008.0066","volume":"25","author":"LM Bowman","year":"2009","unstructured":"Bowman LM, Si E, Pang J, Archibald R, Friedlaender M. Development of a topical polymeric mucoadhesive ocular delivery system for azithromycin. J Ocul Pharmacol Ther. 2009;25(2):133\u20139.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"5","key":"29_CR4","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1089\/jop.2009.0026","volume":"25","author":"EK Akpek","year":"2009","unstructured":"Akpek EK, Vittitow J, Verhoeven RS, et al. Ocular distribution and pharmacokinetics of a novel ophthalmic 1% azithromycin formulation. J Ocul Pharmacol Ther. 2009;25(5):433\u20139.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"1","key":"29_CR5","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1089\/jop.2010.0103","volume":"27","author":"EC Si","year":"2011","unstructured":"Si EC, Bowman LM, Hosseini K. Pharmacokinetic comparisons of bromfenac in DuraSite and Xibrom. J Ocul Pharmacol Ther. 2011;27(1):61\u20136.","journal-title":"J Ocul Pharmacol Ther"},{"key":"29_CR6","first-page":"1369","volume":"5","author":"W Haas","year":"2011","unstructured":"Haas W, Gearinger LS, Usner DW, et al. Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile. Clin Ophthalmol. 2011;5:1369\u201379.","journal-title":"Clin Ophthalmol"},{"key":"29_CR7","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1089\/jop.2006.0137","volume":"23","author":"KW Ward","year":"2007","unstructured":"Ward KW, Lepage J-F, Driot J-Y. Nonclinical pharmacodynamics, pharmacokinetics, and safety of BOL-3032243-A, a novel fluoroquinolone antimicrobial agent for topical ophthalmic use. J Ocul Pharmcol Ther. 2007;23:243\u201356.","journal-title":"J Ocul Pharmcol Ther"},{"key":"29_CR8","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1128\/AAC.00418-09","volume":"53","author":"W Haas","year":"2009","unstructured":"Haas W, Pillar CM, Zurenko GE, et al. Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. Antimicrob Agents Chemother. 2009;53:3552\u201360.","journal-title":"Antimicrob Agents Chemother"},{"key":"29_CR9","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1093\/jac\/dkq127","volume":"65","author":"W Haas","year":"2010","unstructured":"Haas W, Pillar C, Hesje CK, Sanfilippo CM, Morris TW. Bactericidal activity of besifloxacin against staphylococci, Streptococcus pneumoniae and Haemophilus influenzae. J Antimicrob Chemother. 2010;65:1441\u20137.","journal-title":"J Antimicrob Chemother"},{"key":"29_CR10","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.ajo.2011.03.010","volume":"152","author":"W Haas","year":"2011","unstructured":"Haas W, Pillar CM, Torres M, Morris TW, Sahm DF. Monitoring antibiotic resistance in ocular microorganisms: Results from the ARMOR 2009 Surveillance Study. Am J Ophthalmol. 2011;152:567\u201374.","journal-title":"Am J Ophthalmol"},{"key":"29_CR11","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/jac\/dkn528","volume":"63","author":"E Cambau","year":"2009","unstructured":"Cambau E, Matrat S, Xiao-Su P, et al. Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli. J Antimicrob Chemother. 2009;63:443\u201350.","journal-title":"J Antimicrob Chemother"},{"key":"29_CR12","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1159\/000330858","volume":"57","author":"CM Sanfilippo","year":"2011","unstructured":"Sanfilippo CM, Hesje C, Haas W, Morris TW. Topoisomerase mutations that are associated with high-level resistance to earlier fluoroquinolones in Staphylococcus aureus have less effect on the antibacterial activity of besifloxacin. Chemotherapy. 2011;57:363\u201371.","journal-title":"Chemotherapy"},{"key":"29_CR13","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.clinthera.2009.03.010","volume":"31","author":"P Karpecki","year":"2009","unstructured":"Karpecki P, DePaolis M, Hunter JA, et al. Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: a multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study. Clin Ther. 2009;31:514\u201326.","journal-title":"Clin Ther"},{"key":"29_CR14","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1185\/03007990902837919","volume":"25","author":"ME Tepedino","year":"2009","unstructured":"Tepedino ME, Heller WH, Usner DW, et al. Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis. Curr Med Res Opin. 2009;25:1159\u201369.","journal-title":"Curr Med Res Opin"},{"key":"29_CR15","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.ophtha.2009.05.014","volume":"116","author":"MB McDonald","year":"2009","unstructured":"McDonald MB, Protzko EE, Brunner LS, et al. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis. Ophthalmology. 2009;116:1615\u201323.","journal-title":"Ophthalmology"},{"issue":"Suppl","key":"29_CR16","first-page":"29S","volume":"112","author":"HM Leibowitz","year":"1991","unstructured":"Leibowitz HM. Antibacterial effectiveness of ciprofloxacin 0.3% ophthalmic solution in the treatment of bacterial conjunctivitis. Am J Ophthalmol. 1991;112(Suppl):29S\u201333S.","journal-title":"Am J Ophthalmol"},{"key":"29_CR17","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1089\/jop.2008.0116","volume":"25","author":"JW Proksch","year":"2009","unstructured":"Proksch JW, Granvil CP, Siou-Mermet R, et al. Ocular pharmacokinetics of besifloxacin following topical administration to rabbits, monkeys, and humans. J Ocul Pharmacol Ther. 2009;25:335\u201344.","journal-title":"J Ocul Pharmacol Ther"},{"key":"29_CR18","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2165\/11536720-000000000-00000","volume":"30","author":"TL Comstock","year":"2010","unstructured":"Comstock TL, Paterno MR, DeCory HH, Usner DW. Safety and tolerability of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis: data from six clinical and Phase I safety studies. Clin Drug Investig. 2010;30:675\u201385.","journal-title":"Clin Drug Investig"},{"key":"29_CR19","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/j.1442-9071.2007.01552.x","volume":"35","author":"AM Thompson","year":"2007","unstructured":"Thompson AM. Ocular toxicity of fluoroquinolones. Clin Exp Ophthalmol. 2007;35:566\u201377.","journal-title":"Clin Exp Ophthalmol"},{"key":"29_CR20","first-page":"5","volume":"86","author":"H Gunnar","year":"2008","unstructured":"Gunnar H. Acute bacterial conjunctivitis. Acta Ophthalmol. 2008;86:5\u201317.","journal-title":"Acta Ophthalmol"},{"key":"29_CR21","doi-asserted-by":"crossref","unstructured":"Sheikh A, Hurwitz B. Antibiotics versus placebo for acute bacterial conjunctivitis (review). Cochrane Database Syst Rev. 2006;2:CD001211.","DOI":"10.1002\/14651858.CD001211.pub2"},{"issue":"5","key":"29_CR22","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2165\/11632470-000000000-00000","volume":"32","author":"J DeLeon","year":"2012","unstructured":"DeLeon J, Silverstein BE, Allaire C, et al. Besifloxacin ophthalmic suspension 0.6% administered twice daily for 3\u00a0days in the treatment of bacterial conjunctivitis in adults and children. Clin Drug Investig. 2012;32(5):303\u201317.","journal-title":"Clin Drug Investig"},{"key":"29_CR23","first-page":"1433","volume":"6","author":"M Meloni","year":"2012","unstructured":"Meloni M, Cattaneo G, De Servi B. Corneal epithelial toxicity of antiglaucoma formulations: in vitro study of repeated applications. Clin Ophthalmol. 2012;6:1433\u201340.","journal-title":"Clin Ophthalmol"},{"key":"29_CR24","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1007\/s12325-012-0057-1","volume":"29","author":"JT Whitson","year":"2012","unstructured":"Whitson JT, Petroll WM. Corneal epithelial cell viability following exposure to ophthalmic solutions containing preservatives and\/or antihypertensive agents. Adv Ther. 2012;29:874\u201388.","journal-title":"Adv Ther"},{"key":"29_CR25","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1089\/jop.2006.22.267","volume":"22","author":"A Labb\u00e9","year":"2006","unstructured":"Labb\u00e9 A, Pauly A, Liang H, et al. Comparison of toxicological profiles of benzalkonium chloride and polyquaternium-1: an experimental study. J Ocul Pharmacol Ther. 2006;22:267\u201378.","journal-title":"J Ocul Pharmacol Ther"},{"key":"29_CR26","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1167\/iovs.11-8775","volume":"53","author":"J Sarkar","year":"2012","unstructured":"Sarkar J, Chaudhary S, Namavari A, et al. Corneal toxicity due to topical benzalkonium chloride. Invest Ophthalmol Vis Sci. 2012;53:1792\u2013802.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"29_CR27","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1128\/CMR.12.1.147","volume":"12","author":"G McDonnell","year":"1999","unstructured":"McDonnell G, Russell AD. Antiseptics and disinfectants: activity, action, and resistance. Clin Microb Rev. 1999;12:147\u201379.","journal-title":"Clin Microb Rev"},{"key":"29_CR28","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1179\/joc.2007.19.2.146","volume":"19","author":"JM Blondeau","year":"2007","unstructured":"Blondeau JM, Boros S, Hesje CK. Antimicrobial efficacy of gatifloxacin and moxifloxacin with and without benzalkonium chloride compared with ciprofloxacin and levofloxacin against methicillin-resistant Staphylococcus aureus. J Chemother. 2007;19:146\u201351.","journal-title":"J Chemother"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40268-013-0029-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-013-0029-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-013-0029-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,30]],"date-time":"2019-07-30T23:53:30Z","timestamp":1564530810000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40268-013-0029-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,19]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["29"],"URL":"https:\/\/doi.org\/10.1007\/s40268-013-0029-1","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,19]]}}}